Bleakley Financial Group LLC Has $298,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

Bleakley Financial Group LLC trimmed its stake in Edwards Lifesciences Co. (NYSE:EW) by 32.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,521 shares of the medical research company’s stock after selling 2,131 shares during the period. Bleakley Financial Group LLC’s holdings in Edwards Lifesciences were worth $298,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Global Assets Advisory LLC acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $3,053,000. Riverview Trust Co acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $34,000. Brookstone Capital Management grew its holdings in Edwards Lifesciences by 3.2% during the 1st quarter. Brookstone Capital Management now owns 12,275 shares of the medical research company’s stock worth $1,173,000 after acquiring an additional 383 shares during the period. Chesley Taft & Associates LLC grew its holdings in Edwards Lifesciences by 0.6% during the 1st quarter. Chesley Taft & Associates LLC now owns 30,551 shares of the medical research company’s stock worth $2,919,000 after acquiring an additional 184 shares during the period. Finally, 180 Wealth Advisors LLC grew its holdings in Edwards Lifesciences by 1.8% during the 1st quarter. 180 Wealth Advisors LLC now owns 10,124 shares of the medical research company’s stock worth $967,000 after acquiring an additional 183 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on EW. Citigroup decreased their price target on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a report on Tuesday, October 1st. Stifel Nicolaus decreased their price target on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft reduced their target price on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, July 25th. JPMorgan Chase & Co. downgraded Edwards Lifesciences from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $105.00 to $72.00 in a research note on Thursday, July 25th. Finally, Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Fifteen research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and an average price target of $75.81.

Edwards Lifesciences Trading Up 2.0 %

Shares of EW stock opened at $70.63 on Thursday. The company has a 50 day moving average of $68.04 and a 200-day moving average of $78.71. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market cap of $42.56 billion, a P/E ratio of 30.44, a PEG ratio of 2.83 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter last year, the business posted $0.66 EPS. Edwards Lifesciences’s quarterly revenue was up 6.7% compared to the same quarter last year. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,250 shares of company stock worth $1,099,238. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.